Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate mini-dose glucagon in adults with type 1 diabetes using a stable, liquid, ready-to-use preparation. RESEARCH DESIGN AND METHODS: Twelve adults with type 1 diabetes receiving treatment with insulin pumps received subcutaneous doses of 75, 150, and 300 μg of nonaqueous glucagon. Plasma glucose, glucagon, and insulin concentrations were measured. At 180 min, subjects received insulin followed in ˜60 min by a second identical dose of glucagon. RESULTS: Mean (±SE) fasting glucose concentrations (mg/dL) were 110 ± 7, 110 ± 10, and 109 ± 9 for the 75-, 150-, and 300-μg doses, respectively, increasing maximally at 60 min by 33, 64, and 95 mg/dL (all P < 0.001). The post–insulin administration glucose concentrations were 70 ± 2, 74 ± 5, and 70 ± 2 mg/dL, respectively, with maximal increases of 19, 24, and 43 mg/dL post–glucagon administration (P < 0.02) at 45–60 min. CONCLUSIONS: Subcutaneous, nonaqueous, ready-to-use G-Pen Mini glucagon may provide an alternative to oral carbohydrates for the management of anticipated, impending, or mild hypoglycemia in adults with type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schuirmann, D. J. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01068419 · Cited by 2,696
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s009 · Cited by 205
Tse, T. F., Clutter, W. E., Shah, S. D., & Cryer, P. E. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110967 · Cited by 73 · cited 1×
“fects of insulin on glycogen metabolism (10,11).”
Cited by
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
El-Khatib, F. H., Balliro, C., Hillard, M. A., Magyar, K. L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32567-3 · Cited by 254
Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes
Rickels, M. R., DuBose, S. N., Toschi, E., Beck, R. W., Verdejo, A. S., Wolpert, H., Cummins, M. J., Newswanger, B., Riddell, M. C., T1D Exchange Mini-Dose Glucagon Exercise Study Group, et al. (2018) · Diabetes Care · doi:10.2337/dc18-0051 · Cited by 79
“The pharmacokinetic response to the 150-mg dose was almost identical to that reported in the dose-seeking study of the Xeris G-Pen Mini glucagon product (15),”
BackgroundMethodResultInfluentialSelf-citationNovel preparations of glucagon for the prevention and treatment of hypoglycemia
Hawkes, C. P., De Leon, D. D., & Rickels, M. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1216-4 · Cited by 46
Haymond, M. W., DuBose, S. N., Rickels, M. R., Wolpert, H., Shah, V. N., Sherr, J. L., Weinstock, R. S., Agarwal, S., Verdejo, A. S., Cummins, M. J., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00591 · Cited by 42
“(11), and the TABS dosage was the dosage recommended for treating mild hypoglycemia (13).”
BackgroundSelf-citationChristiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002137 · Cited by 22
Self-citation
Metadata
- Authors
- Haymond, M. W., Redondo, M. J., McKay, S., Cummins, M. J., Newswanger, B., Kinzell, J., & Prestrelski, S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-02-09
- Volume
- 39
- Issue
- 3
- Pages
- 465-468
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2284954176
- Cited by
- 39
- References
- 4
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.